Loading…
Atherosclerosis development in apolipoprotein E-null mice deficient for CD69
Aims Atherosclerosis is a chronic inflammatory disease regulated by immune mechanisms. CD69 is a cell surface receptor rapidly induced after leukocyte activation at sites of chronic inflammation. Genetic disruption of CD69 in the mouse aggravates collagen-induced arthritis (CIA), and partial depleti...
Saved in:
Published in: | Cardiovascular research 2009-01, Vol.81 (1), p.197-205 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c419t-33a82336ab24f9e25a29692628e0d853a9302fa007d91c8a85b4844235accd8f3 |
---|---|
cites | cdi_FETCH-LOGICAL-c419t-33a82336ab24f9e25a29692628e0d853a9302fa007d91c8a85b4844235accd8f3 |
container_end_page | 205 |
container_issue | 1 |
container_start_page | 197 |
container_title | Cardiovascular research |
container_volume | 81 |
creator | Gómez, Manuel Sanz-González, Silvia M. Nabah, Yafa Naim Abu Lamana, Amalia Sánchez-Madrid, Francisco Andrés, Vicente |
description | Aims Atherosclerosis is a chronic inflammatory disease regulated by immune mechanisms. CD69 is a cell surface receptor rapidly induced after leukocyte activation at sites of chronic inflammation. Genetic disruption of CD69 in the mouse aggravates collagen-induced arthritis (CIA), and partial depletion of CD69-expressing cells with anti-CD69 monoclonal antibody (mAb) prevents CIA development in wild-type mice, suggesting that this receptor negatively modulates immune and inflammatory responses. It has been recently reported that CD69 is upregulated in a large subset of T cells in atherosclerosis-prone apolipoprotein E-null mice (apoE−/−). In this study, we investigated whether altering CD69 function affects atherosclerosis development. Methods and results We studied native and diet-induced atherosclerosis in apoE−/− and doubly deficient apoE−/−CD69−/− mice and performed expression studies in tissues and primary cells derived from these animals. Plasma cholesterol level was unaffected by CD69 genetic inactivation. Although this genetic manipulation led to an elevated production of interferon γ and interleukin 10 by activated T cells, apoE−/− and apoE−/−CD69−/− mice fed control and high-fat diet exhibited atheromas of similar size and composition when analysed at different stages of the disease. Likewise, anti-CD69 mAb treatment had no effect on plasma cholesterol and atherosclerosis burden in fat-fed apoE−/− mice. Conclusion In contrast to previous studies highlighting the protective function of CD69 against CIA, an autoimmune inflammatory disease, our results rule out a significant role for CD69 against atherosclerosis in apoE−/− mice, an experimental disease model featuring a local inflammatory response triggered and sustained by alterations in lipid homeostasis. |
doi_str_mv | 10.1093/cvr/cvn227 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66734110</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/cvr/cvn227</oup_id><sourcerecordid>66734110</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-33a82336ab24f9e25a29692628e0d853a9302fa007d91c8a85b4844235accd8f3</originalsourceid><addsrcrecordid>eNp90EtLJDEQB_Cw7LIzPi77AaQv60HoNUkl6fRxaJ84sIoKspeQSacxmn6YdIt-ezPMoLc9JKHgR6Xqj9Avgv8QXMKxeQ3pdJQW39CcFJznQBn_juYYY5kLEDBDOzE-pZLzgv1EMyILDBzIHC0X46MNfTR-fbuY1fbV-n5obTdmrsv00Hs39EPoR5vK07ybvM9aZ2ySjTNu7Zo-ZNWJKPfQj0b7aPe37y66Pzu9qy7y5d_zy2qxzA0j5ZgDaEkBhF5R1pSWck1LUVJBpcW15KBLwLTRGBd1SYzUkq-YZIwC18bUsoFddLjpm8Z6mWwcVeuisd7rzvZTVEIUwAjBCR5toEnLxWAbNQTX6vCuCFbr7FTKTm2yS_hg23Vatbb-otuwEvi9BToa7ZugO-Pip6OE0IJx8eX6afj_h_nGuTjat0-pw7NKCxRcXTz8UzdXJ9X1LVD1AB8aEZLi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66734110</pqid></control><display><type>article</type><title>Atherosclerosis development in apolipoprotein E-null mice deficient for CD69</title><source>Oxford Journals Online</source><creator>Gómez, Manuel ; Sanz-González, Silvia M. ; Nabah, Yafa Naim Abu ; Lamana, Amalia ; Sánchez-Madrid, Francisco ; Andrés, Vicente</creator><creatorcontrib>Gómez, Manuel ; Sanz-González, Silvia M. ; Nabah, Yafa Naim Abu ; Lamana, Amalia ; Sánchez-Madrid, Francisco ; Andrés, Vicente</creatorcontrib><description>Aims Atherosclerosis is a chronic inflammatory disease regulated by immune mechanisms. CD69 is a cell surface receptor rapidly induced after leukocyte activation at sites of chronic inflammation. Genetic disruption of CD69 in the mouse aggravates collagen-induced arthritis (CIA), and partial depletion of CD69-expressing cells with anti-CD69 monoclonal antibody (mAb) prevents CIA development in wild-type mice, suggesting that this receptor negatively modulates immune and inflammatory responses. It has been recently reported that CD69 is upregulated in a large subset of T cells in atherosclerosis-prone apolipoprotein E-null mice (apoE−/−). In this study, we investigated whether altering CD69 function affects atherosclerosis development. Methods and results We studied native and diet-induced atherosclerosis in apoE−/− and doubly deficient apoE−/−CD69−/− mice and performed expression studies in tissues and primary cells derived from these animals. Plasma cholesterol level was unaffected by CD69 genetic inactivation. Although this genetic manipulation led to an elevated production of interferon γ and interleukin 10 by activated T cells, apoE−/− and apoE−/−CD69−/− mice fed control and high-fat diet exhibited atheromas of similar size and composition when analysed at different stages of the disease. Likewise, anti-CD69 mAb treatment had no effect on plasma cholesterol and atherosclerosis burden in fat-fed apoE−/− mice. Conclusion In contrast to previous studies highlighting the protective function of CD69 against CIA, an autoimmune inflammatory disease, our results rule out a significant role for CD69 against atherosclerosis in apoE−/− mice, an experimental disease model featuring a local inflammatory response triggered and sustained by alterations in lipid homeostasis.</description><identifier>ISSN: 0008-6363</identifier><identifier>EISSN: 1755-3245</identifier><identifier>DOI: 10.1093/cvr/cvn227</identifier><identifier>PMID: 18703531</identifier><identifier>CODEN: CVREAU</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Animals ; Antibodies, Monoclonal - pharmacology ; Antigens, CD - drug effects ; Antigens, CD - genetics ; Antigens, CD - metabolism ; Antigens, Differentiation, T-Lymphocyte - drug effects ; Antigens, Differentiation, T-Lymphocyte - genetics ; Antigens, Differentiation, T-Lymphocyte - metabolism ; Aorta - metabolism ; Aorta - pathology ; Apolipoprotein E-null mouse ; Apolipoproteins E - genetics ; Apolipoproteins E - metabolism ; Atherosclerosis ; Atherosclerosis (general aspects, experimental research) ; Atherosclerosis - metabolism ; Atherosclerosis - pathology ; Atherosclerosis - physiopathology ; Biological and medical sciences ; Blood and lymphatic vessels ; Cardiology. Vascular system ; CD69 ; Cholesterol - blood ; Disease Models, Animal ; Interferon-gamma - metabolism ; Interleukin-10 - metabolism ; Lectins, C-Type ; Medical sciences ; Mice ; Mice, Inbred C57BL ; Mice, Knockout</subject><ispartof>Cardiovascular research, 2009-01, Vol.81 (1), p.197-205</ispartof><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org 2009</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-33a82336ab24f9e25a29692628e0d853a9302fa007d91c8a85b4844235accd8f3</citedby><cites>FETCH-LOGICAL-c419t-33a82336ab24f9e25a29692628e0d853a9302fa007d91c8a85b4844235accd8f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21127456$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18703531$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gómez, Manuel</creatorcontrib><creatorcontrib>Sanz-González, Silvia M.</creatorcontrib><creatorcontrib>Nabah, Yafa Naim Abu</creatorcontrib><creatorcontrib>Lamana, Amalia</creatorcontrib><creatorcontrib>Sánchez-Madrid, Francisco</creatorcontrib><creatorcontrib>Andrés, Vicente</creatorcontrib><title>Atherosclerosis development in apolipoprotein E-null mice deficient for CD69</title><title>Cardiovascular research</title><addtitle>Cardiovasc Res</addtitle><description>Aims Atherosclerosis is a chronic inflammatory disease regulated by immune mechanisms. CD69 is a cell surface receptor rapidly induced after leukocyte activation at sites of chronic inflammation. Genetic disruption of CD69 in the mouse aggravates collagen-induced arthritis (CIA), and partial depletion of CD69-expressing cells with anti-CD69 monoclonal antibody (mAb) prevents CIA development in wild-type mice, suggesting that this receptor negatively modulates immune and inflammatory responses. It has been recently reported that CD69 is upregulated in a large subset of T cells in atherosclerosis-prone apolipoprotein E-null mice (apoE−/−). In this study, we investigated whether altering CD69 function affects atherosclerosis development. Methods and results We studied native and diet-induced atherosclerosis in apoE−/− and doubly deficient apoE−/−CD69−/− mice and performed expression studies in tissues and primary cells derived from these animals. Plasma cholesterol level was unaffected by CD69 genetic inactivation. Although this genetic manipulation led to an elevated production of interferon γ and interleukin 10 by activated T cells, apoE−/− and apoE−/−CD69−/− mice fed control and high-fat diet exhibited atheromas of similar size and composition when analysed at different stages of the disease. Likewise, anti-CD69 mAb treatment had no effect on plasma cholesterol and atherosclerosis burden in fat-fed apoE−/− mice. Conclusion In contrast to previous studies highlighting the protective function of CD69 against CIA, an autoimmune inflammatory disease, our results rule out a significant role for CD69 against atherosclerosis in apoE−/− mice, an experimental disease model featuring a local inflammatory response triggered and sustained by alterations in lipid homeostasis.</description><subject>Animals</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antigens, CD - drug effects</subject><subject>Antigens, CD - genetics</subject><subject>Antigens, CD - metabolism</subject><subject>Antigens, Differentiation, T-Lymphocyte - drug effects</subject><subject>Antigens, Differentiation, T-Lymphocyte - genetics</subject><subject>Antigens, Differentiation, T-Lymphocyte - metabolism</subject><subject>Aorta - metabolism</subject><subject>Aorta - pathology</subject><subject>Apolipoprotein E-null mouse</subject><subject>Apolipoproteins E - genetics</subject><subject>Apolipoproteins E - metabolism</subject><subject>Atherosclerosis</subject><subject>Atherosclerosis (general aspects, experimental research)</subject><subject>Atherosclerosis - metabolism</subject><subject>Atherosclerosis - pathology</subject><subject>Atherosclerosis - physiopathology</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Cardiology. Vascular system</subject><subject>CD69</subject><subject>Cholesterol - blood</subject><subject>Disease Models, Animal</subject><subject>Interferon-gamma - metabolism</subject><subject>Interleukin-10 - metabolism</subject><subject>Lectins, C-Type</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Knockout</subject><issn>0008-6363</issn><issn>1755-3245</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNp90EtLJDEQB_Cw7LIzPi77AaQv60HoNUkl6fRxaJ84sIoKspeQSacxmn6YdIt-ezPMoLc9JKHgR6Xqj9Avgv8QXMKxeQ3pdJQW39CcFJznQBn_juYYY5kLEDBDOzE-pZLzgv1EMyILDBzIHC0X46MNfTR-fbuY1fbV-n5obTdmrsv00Hs39EPoR5vK07ybvM9aZ2ySjTNu7Zo-ZNWJKPfQj0b7aPe37y66Pzu9qy7y5d_zy2qxzA0j5ZgDaEkBhF5R1pSWck1LUVJBpcW15KBLwLTRGBd1SYzUkq-YZIwC18bUsoFddLjpm8Z6mWwcVeuisd7rzvZTVEIUwAjBCR5toEnLxWAbNQTX6vCuCFbr7FTKTm2yS_hg23Vatbb-otuwEvi9BToa7ZugO-Pip6OE0IJx8eX6afj_h_nGuTjat0-pw7NKCxRcXTz8UzdXJ9X1LVD1AB8aEZLi</recordid><startdate>20090101</startdate><enddate>20090101</enddate><creator>Gómez, Manuel</creator><creator>Sanz-González, Silvia M.</creator><creator>Nabah, Yafa Naim Abu</creator><creator>Lamana, Amalia</creator><creator>Sánchez-Madrid, Francisco</creator><creator>Andrés, Vicente</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20090101</creationdate><title>Atherosclerosis development in apolipoprotein E-null mice deficient for CD69</title><author>Gómez, Manuel ; Sanz-González, Silvia M. ; Nabah, Yafa Naim Abu ; Lamana, Amalia ; Sánchez-Madrid, Francisco ; Andrés, Vicente</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-33a82336ab24f9e25a29692628e0d853a9302fa007d91c8a85b4844235accd8f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Animals</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antigens, CD - drug effects</topic><topic>Antigens, CD - genetics</topic><topic>Antigens, CD - metabolism</topic><topic>Antigens, Differentiation, T-Lymphocyte - drug effects</topic><topic>Antigens, Differentiation, T-Lymphocyte - genetics</topic><topic>Antigens, Differentiation, T-Lymphocyte - metabolism</topic><topic>Aorta - metabolism</topic><topic>Aorta - pathology</topic><topic>Apolipoprotein E-null mouse</topic><topic>Apolipoproteins E - genetics</topic><topic>Apolipoproteins E - metabolism</topic><topic>Atherosclerosis</topic><topic>Atherosclerosis (general aspects, experimental research)</topic><topic>Atherosclerosis - metabolism</topic><topic>Atherosclerosis - pathology</topic><topic>Atherosclerosis - physiopathology</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Cardiology. Vascular system</topic><topic>CD69</topic><topic>Cholesterol - blood</topic><topic>Disease Models, Animal</topic><topic>Interferon-gamma - metabolism</topic><topic>Interleukin-10 - metabolism</topic><topic>Lectins, C-Type</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Knockout</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gómez, Manuel</creatorcontrib><creatorcontrib>Sanz-González, Silvia M.</creatorcontrib><creatorcontrib>Nabah, Yafa Naim Abu</creatorcontrib><creatorcontrib>Lamana, Amalia</creatorcontrib><creatorcontrib>Sánchez-Madrid, Francisco</creatorcontrib><creatorcontrib>Andrés, Vicente</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cardiovascular research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gómez, Manuel</au><au>Sanz-González, Silvia M.</au><au>Nabah, Yafa Naim Abu</au><au>Lamana, Amalia</au><au>Sánchez-Madrid, Francisco</au><au>Andrés, Vicente</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Atherosclerosis development in apolipoprotein E-null mice deficient for CD69</atitle><jtitle>Cardiovascular research</jtitle><addtitle>Cardiovasc Res</addtitle><date>2009-01-01</date><risdate>2009</risdate><volume>81</volume><issue>1</issue><spage>197</spage><epage>205</epage><pages>197-205</pages><issn>0008-6363</issn><eissn>1755-3245</eissn><coden>CVREAU</coden><abstract>Aims Atherosclerosis is a chronic inflammatory disease regulated by immune mechanisms. CD69 is a cell surface receptor rapidly induced after leukocyte activation at sites of chronic inflammation. Genetic disruption of CD69 in the mouse aggravates collagen-induced arthritis (CIA), and partial depletion of CD69-expressing cells with anti-CD69 monoclonal antibody (mAb) prevents CIA development in wild-type mice, suggesting that this receptor negatively modulates immune and inflammatory responses. It has been recently reported that CD69 is upregulated in a large subset of T cells in atherosclerosis-prone apolipoprotein E-null mice (apoE−/−). In this study, we investigated whether altering CD69 function affects atherosclerosis development. Methods and results We studied native and diet-induced atherosclerosis in apoE−/− and doubly deficient apoE−/−CD69−/− mice and performed expression studies in tissues and primary cells derived from these animals. Plasma cholesterol level was unaffected by CD69 genetic inactivation. Although this genetic manipulation led to an elevated production of interferon γ and interleukin 10 by activated T cells, apoE−/− and apoE−/−CD69−/− mice fed control and high-fat diet exhibited atheromas of similar size and composition when analysed at different stages of the disease. Likewise, anti-CD69 mAb treatment had no effect on plasma cholesterol and atherosclerosis burden in fat-fed apoE−/− mice. Conclusion In contrast to previous studies highlighting the protective function of CD69 against CIA, an autoimmune inflammatory disease, our results rule out a significant role for CD69 against atherosclerosis in apoE−/− mice, an experimental disease model featuring a local inflammatory response triggered and sustained by alterations in lipid homeostasis.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>18703531</pmid><doi>10.1093/cvr/cvn227</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0008-6363 |
ispartof | Cardiovascular research, 2009-01, Vol.81 (1), p.197-205 |
issn | 0008-6363 1755-3245 |
language | eng |
recordid | cdi_proquest_miscellaneous_66734110 |
source | Oxford Journals Online |
subjects | Animals Antibodies, Monoclonal - pharmacology Antigens, CD - drug effects Antigens, CD - genetics Antigens, CD - metabolism Antigens, Differentiation, T-Lymphocyte - drug effects Antigens, Differentiation, T-Lymphocyte - genetics Antigens, Differentiation, T-Lymphocyte - metabolism Aorta - metabolism Aorta - pathology Apolipoprotein E-null mouse Apolipoproteins E - genetics Apolipoproteins E - metabolism Atherosclerosis Atherosclerosis (general aspects, experimental research) Atherosclerosis - metabolism Atherosclerosis - pathology Atherosclerosis - physiopathology Biological and medical sciences Blood and lymphatic vessels Cardiology. Vascular system CD69 Cholesterol - blood Disease Models, Animal Interferon-gamma - metabolism Interleukin-10 - metabolism Lectins, C-Type Medical sciences Mice Mice, Inbred C57BL Mice, Knockout |
title | Atherosclerosis development in apolipoprotein E-null mice deficient for CD69 |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T19%3A32%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Atherosclerosis%20development%20in%20apolipoprotein%20E-null%20mice%20deficient%20for%20CD69&rft.jtitle=Cardiovascular%20research&rft.au=G%C3%B3mez,%20Manuel&rft.date=2009-01-01&rft.volume=81&rft.issue=1&rft.spage=197&rft.epage=205&rft.pages=197-205&rft.issn=0008-6363&rft.eissn=1755-3245&rft.coden=CVREAU&rft_id=info:doi/10.1093/cvr/cvn227&rft_dat=%3Cproquest_cross%3E66734110%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c419t-33a82336ab24f9e25a29692628e0d853a9302fa007d91c8a85b4844235accd8f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=66734110&rft_id=info:pmid/18703531&rft_oup_id=10.1093/cvr/cvn227&rfr_iscdi=true |